- •Normal baseline CA125 prior to chemotherapy is associated with better survival in high-risk early-stage ovarian cancer.
- •Normalization of CA125 after the first cycle of chemotherapy is associated improved survival in early-stage ovarian cancer.
- •Percent decline and absolute nadir normal value of CA125 were not predictive of outcome in early-stage ovarian cancer.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N. Engl. J. Med. 1983; 309: 883-887
- Progress in the management of gynecologic cancer: consensus summary statement.J. Clin. Oncol. 2003; 21 (129s–32s)
- Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.Ann. Oncol. 1996; 7: 361-364
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.J. Clin. Oncol. 1991; 9: 389-393
- CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.Gynecol. Oncol. 2007; 104: 176-180
- Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.Gynecol. Oncol. 2006; 103: 195-198
- Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.J. Clin. Oncol. 2006; 24: 1454-1458
- Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.N. Engl. J. Med. 1990; 322: 1021-1027
- Ovarian cancer statistics, 2018.CA Cancer J. Clin. 2018; 68: 284-296
- Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.Gynecol. Oncol. 2006; 102: 432-439
- Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.Obstet. Gynecol. 1995; 86: 259-264
- Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.J. Clin. Oncol. 2005; 23: 5938-5942
- Preoperative serum CA125 in surgical stage 1 epithelial ovarian cancer.Gynecol. Oncol. 2007; 107: 357-358
- Analysis of survival by tumor response.J. Clin. Oncol. 1983; 1: 710-719
- The role of CA 125 as tumor marker: biochemical and clinical aspects.Adv. Exp. Med. Biol. 2015; 867: 229-244
- The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian Cancer (PLCO) screening trial.Gynecol. Oncol. 2008; 110: 383-389
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.Gynecol. Oncol. 2008; 109: 370-376
- Ovarian cancer: a clinical challenge that needs some basic answers.PLoS Med. 2009; 6e25
- Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.Gynecol. Oncol. 2010; 116: 57-60
- Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.Ann. Oncol. 2008; 19: 327-331
- CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.Gynecol. Oncol. 2010; 119: 265-269
- Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.J. Ovarian. Res. 2013; 6: 31
- The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.Gynecol. Oncol. 2010; 116: 301-306
- Application of cell-free DNA analysis to cancer treatment.N. Engl. J. Med. 2018; 379: 1754-1765
- Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).Gynecol. Oncol. 2015; 137: 229-238
- Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study.PLoS Med. 2016; 13e1002198
- Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction.Cell. 2019; 178: 699-713.e19
- A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.Gynecol. Oncol. 2011; 122: 89-94
- European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.Gynecol. Oncol. 2020; 156: 265-270
- Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.Gynecol. Oncol. 2020; 159: 604-606